X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Bevacizumab is a vascular endothelial growth factor inhibitor for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.
Lead Product(s): Bevacizumab
Therapeutic Area: Oncology Product Name: Avastin-Generic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
Through collaboration, Lupin with Enzene will launch enz-124 (cetuximab) in India, the 1st biosimilar developed for Cetuximab, sold under the brand Erbitux. Cetuximab, a chimeric monoclonal antibody, is used as a targeted therapy for metastatic colorectal cancer and SCCHN.
Lead Product(s): Cetuximab
Therapeutic Area: Oncology Product Name: enz-124
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lupin Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 30, 2023
Details:
Adalimumab-bwwd is being launched for treating autoimmune disease like rheumatoid arthritis and ankylosis spondylitis. The drug bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface.
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
Zidavi, which is a novel combination of ceftazidime and avibactam, a preferred treatment against OXA-48-like and Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae for pyelonephritis or Complicated Urinary Tract Infections.
Lead Product(s): Ceftazidime,Avibactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Zidavi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2023
Details:
Theramex has entered into an agreement with Enzene Biosciences to develop, register and commercialise a biosimilar drug of Roche’s reference medicine RoActemra® (Tocilizumab). Tocilizumab will be available in parenteral vials, subcutaneous prefilled syringes and autoinjectors.
Lead Product(s): Tocilizumab,Methotrexate
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Theramex
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 23, 2021
Details:
Ibuprofen and Famotidine Tablets is AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis® Tablets, 800 mg/26.6 mg.
Lead Product(s): Ibuprofen,Famotidine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2021
Details:
Avipiravir has received authorization from the Drug Controller General of India (DCGI) for restricted emergency use in India.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Alfluenza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
